AROLDI, ANDREA

AROLDI, ANDREA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 13 di 13 (tempo di esecuzione: 0.018 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 01 - Articolo su rivista 2023 Aroldi, AndreaAngaroni, FabrizioD’Aliberti, DeborahSpinelli, SilviaCrespiatico, IlariaCrippa, ValentinaPiazza, RoccoGraudenzi, AlexRamazzotti, Daniele
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success 01 - Articolo su rivista 2022 Inzoli E.Aroldi A.Piazza R.Gambacorti Passerini C.
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 01 - Articolo su rivista 2021 Aroldi, AGambacorti Passerini, C +
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies 01 - Articolo su rivista 2021 Gambacorti Passerini C.Aroldi A.Piazza R. +
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 01 - Articolo su rivista 2020 Fontana, DilettaRamazzotti, DanieleAroldi, AndreaRedaelli, SaraMagistroni, VeraPirola, AlessandraMassimino, LucaMastini, CristinaBombelli, SilviaElli, Elena MariaFumagalli, MonicaPerego, Roberto APagni, FabioMologni, LucaPiazza, RoccoGambacorti-Passerini, Carlo +
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 01 - Articolo su rivista 2020 Bossi E.Aroldi A.Steidl C.Verga L.Fontana D.Sharma G. G.Mologni L.Piazza R.Gambacorti Passerini C. +
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 01 - Articolo su rivista 2019 Elli E.Aroldi A. +
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 02 - Intervento a convegno 2019 Diletta FontanaDaniele RamazzottiAndrea AroldiLuca MassiminoElena Maria ElliMonica FumagalliRocco PiazzaCarlo Gambacorti-Passerini +
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 01 - Articolo su rivista 2019 Aroldi A.Gambacorti-Passerini C.Antolini L. +
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea 01 - Articolo su rivista 2018 Aroldi, AndreaPioltelli, PietroGambacorti-Passerini, Carlo +
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 01 - Articolo su rivista 2016 Aroldi A.Pioltelli P. E.Pogliani E. M.Elli E. M. +
Chronic myeloid leukemia: Second-line drugs of choice 01 - Articolo su rivista 2016 GAMBACORTI PASSERINI, CARLOAroldi, ACORDANI, NICOLETTAPIAZZA, ROCCO GIOVANNI
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 01 - Articolo su rivista 2014 Elli E. M.Aroldi A.Pioltelli P.Pogliani E. M. +